An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer.
about
Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives.Molecular biology of liver cancer stem cells.Nuclear and cytoplasmic accumulation of Ep-ICD is frequently detected in human epithelial cancers.Predicting targeted drug combinations based on Pareto optimal patterns of coexpression network connectivityRNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule.Effects of EpCAM overexpression on human breast cancer cell linesEpothilone B enhances surface EpCAM expression in ovarian cancer Hey cellsNuclear Ep-ICD accumulation predicts aggressive clinical course in early stage breast cancer patients.High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibodyPhenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell lines.EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysisNuclear Ep-ICD expression is a predictor of poor prognosis in "low risk" prostate adenocarcinomasEpCAM Aptamer-siRNA Chimera Targets and Regress Epithelial CancerSuperior Performance of Aptamer in Tumor Penetration over Antibody: Implication of Aptamer-Based Theranostics in Solid TumorsPivotal role of epithelial cell adhesion molecule in the survival of lung cancer cells.Subcellular differential expression of Ep-ICD in oral dysplasia and cancer is associated with disease progression and prognosisAn anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer.EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2(+), basal-like, and HER2 intrinsic subtypes of breast cancer.Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.EpCAM overexpression prolongs proliferative capacity of primary human breast epithelial cells and supports hyperplastic growth.Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside.Breast cancer prognostic markers in the post-genomic era.Radioimmunotherapy of solid tumors: searching for the right target.EpCAM and its potential role in tumor-initiating cells.Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy.Monoclonal antibodies against human cancer stem cells.A strain-promoted alkyne-azide cycloaddition (SPAAC) reaction of a novel EpCAM aptamer-fluorescent conjugate for imaging of cancer cells.Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment.The activity of γδ T cells against paediatric liver tumour cells and spheroids in cell culture.EPCAM-A novel molecular target for the treatment of pediatric and adult germ cell tumors.Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.Predominant expression of truncated EpCAM is associated with a more aggressive phenotype and predicts poor overall survival in colorectal cancer.Is Ep-CAM Expression a Diagnostic and Prognostic Biomarker for Colorectal Cancer? A Systematic Meta-Analysis.Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies.Use of Ber-EP4 and Epithelial Specific Antigen to Differentiate Clinical Simulators of Basal Cell Carcinoma.EpCAM expression is an indicator of recurrence in basal-like breast cancer.Antineoplastic effects of clove buds (Syzygium aromaticum L.) in the model of breast carcinoma.EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs.Immunotherapy as an Option for Cancer Treatment.Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection.
P2860
Q33755476-25EE884D-FEBA-43D7-9805-AB3CEE191912Q33756006-BC2536CE-C85C-485A-AF49-8FBB2F6578B8Q33770286-F2C76D8F-2A5A-4B00-AC54-7C1B61F07633Q33772585-3EA343B6-343A-4BD0-B9B1-BEE430BDAC72Q33807710-C796568B-FE8C-4942-9D9F-F83C4DD19AF3Q33807783-41D04281-ABDD-4542-811C-096E8D353D75Q34188631-48AA86E4-026E-4A37-A05D-A2DA7BC910BDQ34308781-0A66FEE5-5C25-4DCA-BA61-5F95EA901EA3Q34361383-26266A85-9100-4904-BCC8-1D932B2C6C9CQ34461481-AECD4549-5F02-4CD5-8FAF-0572A21CEA6FQ34934911-84ACA053-F522-4C84-8275-AC5541B0063DQ35103343-772F3148-1824-4B20-994A-6B17C324B470Q35691811-8E93CEC4-5A1F-4BF6-A97A-A7B1F0A6CBDDQ35868868-B0AC0DFE-E415-44EA-A43F-7AF69F50CAADQ36054961-8DA8E149-C2F3-4BAD-96B9-FADA8CFE2F85Q36078946-D26C4C2C-7358-4DCC-96F7-27FB930DD9A9Q36413078-41EF497F-DECD-4070-B7A1-2FFC77FF98A6Q36775366-AF1F806B-C271-4FB1-B8A4-CFC40CFB8C11Q36983909-5312AC50-D4C1-46BD-AC3B-8462A3659394Q36985597-906D9792-C1A2-40AC-B607-4F5B59A1F347Q37738903-9C06B6C0-B7FE-441D-8E8A-4D1C7C3C623DQ37750543-46AA3BB8-FA37-42ED-B1E1-93B82939CD10Q37804904-D59BDE32-3B22-4D80-9C25-F538E4EA5D69Q38014664-995EB068-239C-4706-83E4-BAA36AB90BDCQ38073792-6CB5C016-5650-4E2B-BCEA-4A26C5ACEE23Q38206818-B01B2860-03FD-4F09-BE99-A7D2B3DA73EEQ38305909-14A33883-DE46-4A0E-B04B-094BCEF06E66Q39177087-85FA2EC2-AEA1-44F5-BC3D-15B0B67E202FQ39255203-EBC93C04-073B-4667-BA87-6BDCA6F713A8Q39276591-4BADF184-A1B2-42E7-8C36-003239A38BE3Q39372518-2979B229-A5C7-4DDA-ACD3-41D2791AA5A4Q40842917-0F42F58C-AF92-40BA-BF43-BC53719EBDE8Q41084422-2D026E4A-CBA5-4A77-A0B4-8857060AE0B8Q41670912-F035054D-2169-4312-83BF-098191ACFE80Q42154694-A5141C2A-EE8C-4043-94A7-544B9D2A186CQ42496058-84101975-C4D8-46D7-99D2-D09AF46C05C0Q44282819-4A6C6D56-6BC1-4CD6-9E2E-4432C6417B53Q47735319-2ADDD812-0FCA-4B9F-967A-3BFE803B2FDAQ48194503-21E2A978-C2F2-4215-AD7E-D53A2F40ECAEQ50041876-351D841F-2C26-47CB-BC35-1BC1C2994A82
P2860
An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
An open-label, randomized phas ...... with metastatic breast cancer.
@ast
An open-label, randomized phas ...... with metastatic breast cancer.
@en
An open-label, randomized phas ...... with metastatic breast cancer.
@nl
type
label
An open-label, randomized phas ...... with metastatic breast cancer.
@ast
An open-label, randomized phas ...... with metastatic breast cancer.
@en
An open-label, randomized phas ...... with metastatic breast cancer.
@nl
prefLabel
An open-label, randomized phas ...... with metastatic breast cancer.
@ast
An open-label, randomized phas ...... with metastatic breast cancer.
@en
An open-label, randomized phas ...... with metastatic breast cancer.
@nl
P2093
P2860
P356
P1433
P1476
An open-label, randomized phas ...... with metastatic breast cancer.
@en
P2093
C Dittrich
C Reinhardt
D Rüttinger
M E Scheulen
N Marschner
P2860
P304
P356
10.1093/ANNONC/MDP314
P577
2009-07-24T00:00:00Z